...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of atherosclerosis and thrombosis. >Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan
【24h】

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

机译：日本家族性高胆固醇血症患者的治疗方式和血脂谱

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim : To evaluate the epidemiology and real-world treatment patterns associated with lipid-modifying therapies (LMTs) among groups of Japanese patients with familial hypercholesterolemia (FH). Methods : A retrospective observational study was conducted using an electronic hospital-based administrative claims database and electronic medical records. Patients with existing diagnosis of FH (FH-D) and patients with suspected FH (FH-S) defined by low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL were included, and medical records of hospitals across Japan were analyzed to assess the diagnostic status, management of LDL-C levels, and treatment patterns. Results : Among the 3,495 patients who met the inclusion criteria, 193 patients were FH-D and 3,339 patients were FH-S. Among them, 83.5% had not achieved the LDL-C of ＜ 100 mg/dL recommended for patients with FH at the index date. Mean LDL-C levels for all patients and for FH-D and FH-S patients were 145.8 mg/dL, 119.2 mg/dL, and 147.6 mg/dL, respectively. 44.5% of the patients were not currently treated with LMTs. High-intensity statins were used only in 19.2% and 2.3% of the FH-D and FH-S patients, respectively. Furthermore, among the FH-D and FH-S statin-treated patients, 61 (69.3%) and 1,059 (89.7%) remained on monotherapy even when their LDL-C was ≥100 mg/dL. Conclusions : Treatment and management of LDL-C in Japanese FH patients remain suboptimal. The results suggest that FH is underdiagnosed in real-world, routine clinical practice in Japan. There is an urgent need to improve the diagnostic rate of FH and to provide the appropriate therapy to achieve the recommended LDL-C levels of ＜ 100 mg/dL or a more than 50% reduction for patients with FH in Japan.
机译：目的：评估家族性高胆固醇血症（FH）的日本患者群体中与脂质修饰疗法（LMT）相关的流行病学和现实治疗模式。方法：使用基于电子医院的行政理赔数据库和电子病历进行回顾性观察研究。包括已诊断为FH（FH-D）的患者和以低密度脂蛋白胆固醇（LDL-C）≥190mg / dL定义的可疑FH（FH-S）患者，并分析了日本各地医院的医疗记录评估诊断状态，LDL-C水平管理和治疗模式。结果：在符合入选标准的3495例患者中，有193例为FH-D，有3339例为FH-S。其中，有83.5％的患者在指标日期未达到FH推荐的LDL-C≤100 mg / dL。所有患者以及FH-D和FH-S患者的平均LDL-C水平分别为145.8 mg / dL，119.2 mg / dL和147.6 mg / dL。目前有44.5％的患者未接受LMT治疗。高强度他汀类药物仅分别用于FH-D和FH-S患者的19.2％和2.3％。此外，在接受FH-D和FH-S他汀类药物治疗的患者中，即使LDL-C≥100 mg / dL，仍接受单药治疗的仍为61（69.3％）和1,059（89.7％）。结论：日本FH患者的LDL-C的治疗和管理仍欠佳。结果表明，在日本，FH在现实世界的常规临床实践中诊断不足。迫切需要提高FH的诊断率并提供适当的治疗方法，以使日本的FH患者的LDL-C推荐水平达到＜100 mg / dL或降低50％以上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号